HC Wainwright Analysts Increase Earnings Estimates for ADAP

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – HC Wainwright increased their FY2024 earnings per share estimates for Adaptimmune Therapeutics in a report released on Thursday, November 14th. HC Wainwright analyst A. He now forecasts that the biotechnology company will post earnings of ($0.12) per share for the year, up from their prior forecast of ($0.30). HC Wainwright currently has a “Buy” rating and a $3.50 target price on the stock. The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.19) per share. HC Wainwright also issued estimates for Adaptimmune Therapeutics’ FY2025 earnings at ($0.54) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at ($0.12) EPS and FY2028 earnings at $0.06 EPS.

A number of other equities research analysts have also recently issued reports on ADAP. StockNews.com cut shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday. Guggenheim reduced their price objective on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Friday. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $3.16.

Adaptimmune Therapeutics Trading Down 0.8 %

Shares of Adaptimmune Therapeutics stock opened at $0.59 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.09. The company’s fifty day moving average price is $0.88 and its two-hundred day moving average price is $1.03. The firm has a market capitalization of $150.02 million, a PE ratio of -2.67 and a beta of 2.26. Adaptimmune Therapeutics has a 52-week low of $0.42 and a 52-week high of $2.05.

Institutional Trading of Adaptimmune Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Long Focus Capital Management LLC increased its position in shares of Adaptimmune Therapeutics by 15.6% during the 2nd quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock worth $12,037,000 after purchasing an additional 1,662,184 shares during the last quarter. Baillie Gifford & Co. raised its stake in Adaptimmune Therapeutics by 10.7% in the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock valued at $15,944,000 after acquiring an additional 1,626,657 shares during the period. Renaissance Technologies LLC lifted its holdings in Adaptimmune Therapeutics by 28.3% during the 2nd quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock valued at $1,742,000 after purchasing an additional 394,566 shares during the last quarter. Vontobel Holding Ltd. boosted its position in Adaptimmune Therapeutics by 230.8% during the third quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 30,000 shares during the period. Finally, Fullcircle Wealth LLC acquired a new position in shares of Adaptimmune Therapeutics in the third quarter valued at $33,000. Institutional investors and hedge funds own 31.37% of the company’s stock.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.